Dulaglutide

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.

Mechanism of Action

GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression.

Typical Dosage (Research)

Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response.

Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens.

Side Effects & Risks

Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration.

Same class warnings: thyroid tumors, pancreatitis, diabetic retinopathy complications. Avoid in severe GI disease.

Who Uses Dulaglutide

Type 2 diabetics preferring once-weekly dosing, those seeking cardiovascular benefits (shown to reduce MACE), patients wanting moderate weight loss.